Is angioedema a side effect of losartan (angiotensin‑II receptor blocker) or lisinopril (angiotensin‑converting enzyme inhibitor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Angioedema Risk: Both Drugs, But Lisinopril is Worse

Angioedema is a known side effect of both lisinopril (ACE inhibitor) and losartan (ARB), but lisinopril carries a significantly higher risk—occurring in fewer than 1% of patients—while losartan-induced angioedema is much less frequent. 1, 2, 3

Understanding the Risk Profile

Lisinopril (ACE Inhibitor)

  • Incidence: Occurs in <1% of patients, but more frequent in Black patients 1
  • Mechanism: ACE inhibitors block the degradation of bradykinin, leading to its accumulation, which triggers angioedema 4, 2
  • Timing: Most commonly occurs within the first month of therapy, but can occur even after many years of continuous use 4, 2
  • Severity: Can be life-threatening with involvement of the tongue, glottis, or larynx causing airway obstruction 2, 5
  • Management response: Does NOT reliably respond to epinephrine, antihistamines, or corticosteroids 4

Losartan (ARB)

  • Incidence: "Much less frequent" than ACE inhibitors 1
  • Mechanism: ARBs do not inhibit bradykinin degradation like ACE inhibitors, which theoretically should reduce angioedema risk 3
  • Cross-reactivity concern: Despite lower risk, documented cases exist of patients developing angioedema with ARBs after previous ACE inhibitor-induced angioedema 1, 3
  • FDA labeling: Losartan's label specifically notes angioedema has occurred, "including some patients who previously experienced angioedema with other drugs including ACE inhibitors" 3

Critical Clinical Decision Points

If Angioedema Occurs on Lisinopril:

  1. Immediately discontinue the medication 1, 2
  2. Never rechallenge with any ACE inhibitor—this is a lifetime contraindication 1
  3. The tendency to swell can persist for up to 6 weeks after discontinuation 4

Switching from ACE Inhibitor to ARB After Angioedema:

Exercise extreme caution. 1

  • While ARBs are considered as alternative therapy, "there are a number of patients who have also developed angioedema with ARBs" 1
  • The guidelines state: "extreme caution is advised when substituting an ARB in a patient who has had angioedema associated with ACEI use" 1, 6
  • However, most patients who experienced ACE inhibitor-induced angioedema can safely use ARBs without recurrence 4

Key Pitfalls to Avoid:

  1. Don't assume ARBs are completely safe after ACE inhibitor-induced angioedema—cross-reactivity exists 7, 8, 9, 10
  2. Don't treat with standard allergy medications alone—ACEI-induced angioedema is bradykinin-mediated, not histamine-mediated, so antihistamines and steroids are often ineffective 4, 11
  3. Don't miss intestinal angioedema—can present as abdominal pain without facial swelling 2, 12
  4. Don't overlook late-onset cases—angioedema can occur after years of stable therapy 4, 13

Race-Based Considerations

African American patients face higher risk of ACE inhibitor-induced angioedema 1, 4. This population requires particularly vigilant monitoring and lower threshold for considering ARB alternatives from the outset.

Evidence Strength

The guideline evidence is consistent across multiple ACC/AHA publications 1, 6, 1, with FDA drug labels corroborating these risks 2, 3. Recent case reports continue to document both lisinopril-induced 13, 5, 12, 11 and losartan-induced 7, 8, 9, 10 angioedema, confirming this remains a clinically relevant concern.

References

Research

Fatal angioedema associated with lisinopril.

The Annals of pharmacotherapy, 1992

Research

Losartan-induced Angioedema: A Case Report and Review of Literature.

Journal of community hospital internal medicine perspectives, 2026

Research

Angioedema associated with lisinopril.

The American journal of emergency medicine, 1992

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.